- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Scientists Identify a Novel Wnt Signaling Regulator in Colorectal and Endometrial Cancers
The gene mutation in RNF43, previously missed in The Cancer Genome Atlas study, was identified in 20% of colorectal and endometrial cancers.
Scientists have identified a genetic mutation in about 20% of colorectal and endometrial cancers that had been overlooked in recent large, comprehensive gene searches. With this discovery, the altered gene, called RNF43, now ranks as one of the most common mutations in the 2 cancer types.
Reporting in Nature Genetics, investigators from Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard said the mutated gene helps control an important cell-signaling pathway, Wnt, that has been implicated in many forms of cancer. They suggest that having a mutation in RNF43 may serve as a biomarker that identifies patients with colorectal and endometrial cancer who could benefit from precision cancer drugs that target the Wnt pathway, although no such drugs have yet been approved.
Read the complete press release by Dana Farber: http://bit.ly/1tcF6NW
Link to the paper on Nature Genetics: http://bit.ly/1pO60Xa
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
